Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram ...

May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences ... ABI-6250: An oral viral entry inhibitor candidate for hepatitis D virus (HDV) infection The late-breaker poster presentation titled ...

the virus and result in very low cure rates. No new mechanisms of action have been approved for the treatment of cHBV infection in over 25 years. Assembly Bio intends to make the posters available ...

Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, ...

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced data from its herpes simplex virus (HSV ...

April 09, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced data from its ...

Justin Trudeau to step down as head of Canada’s Liberal Party: What happens now Blinken says Ukraine's position in Kursk ‘important’ for negotiations Italy plans $1.6 billion deal with Elon ...

and efficacy results from participants with chronic hepatitis B virus (HBV) infection in its ongoing Phase 1b study evaluating ABI-4334, an investigational next-generation capsid assembly ...

June 05, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences ... small molecule hepatitis D virus (HDV) entry inhibitor candidate, featured in a poster presentation at the European Association for ...

with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV). Assembly Bio’s current portfolio of small molecule antiviral ...